Hmox1 inducers

A compound represented by structural formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is 5-7 membered monocyclic cycloalkyl, 5-7 membered monocyclic heterocyclyl, 5-6 membered heteroaryl, or phenyl;
• X is —S—, —O—, or —NRb—;
• when X is —S— and ring A is phenyl, then R is 3-7 membered monocyclic heterocyclyl optionally substituted with one or more groups selected from the group consisting of halo, —CN, —OH, —(C1-C4)alkyl, —(C1-C4)haloalkyl, —(C1-C4)hydroxyalkyl, —(C1-C4)alkoxy, —(C1-C4)haloalkoxy, and —NRaRa;
• when X is —S— and ring A is 5-7 membered monocyclic cycloalkyl, 5-7 membered monocyclic heterocyclyl, or 5-6 membered heteroaryl;
• or when X is —O— or —NRb—;
• then R is —H, —(C1-C4)alkyl, or —(CH2)i3-7 membered monocyclic heterocyclyl, wherein the —(C1-C4)alkyl or 3-7 membered monocyclic heterocyclyl represented by R is optionally substituted with one or more groups selected from the group consisting of halo, —CN, —OH, —(C1-C4)alkyl, —(C1-C4)haloalkyl, —(C1-C4)hydroxyalkyl, —(C1-C4)alkoxy, —(C1-C4)haloalkoxy, —SO2Ra, and —NRaRa;
• each R1 is independently —H, halogen, —(CH2)kCOOH, —(CH2)kCO(C1-C4)alkyl, —(CH2)kCOO(C1-C4)alkyl, —(CH2)pC(═O)NRaR3, —CH(CF3)NRaR3, —C(═NOH)CF3, or —CH(CF3)OR3, wherein the (C1-C4)alkyl in the group represented by R1 is optionally substituted with one or more groups selected from the group consisting of halo, —CN, —OH, —(C1-C4)hydroxyalkyl, —(C1-C4)alkoxy, —(C1-C4)haloalkoxy, and —NRaRa;
• each R2 is independently —H, halo, CN, —(C1-C4)alkyl, —OH, —(C1-C4)alkoxy, —COOH, —C(═O)(C1-C4)alkyl, —C(═O)O(C1-C4)alkyl, —C(═O)NRa(C1-C4)alkyl, —NRaRa, 3-6 membered monocyclic cycloalkyl, —O(CH2)i3-7 membered monocyclic heterocyclyl, 3-7 membered monocyclic heterocyclyl, or 5-6 membered heteroaryl, wherein the —(C1-C4)alkyl, —(C1-C4)alkoxy, heterocyclyl, or heteroaryl represented by R2 or in the group represented by R2 is optionally substituted with one or more groups selected from the group consisting of halo, —CN, —OH, —(C1-C4)alkyl, —(C1-C4)alkoxy, —(C1-C4)haloalkyl, —(C1-C4)hydroxyalkyl, —(C1-C4)haloalkoxy, and —NRaRa;
• each R3 is independently H, (C1-C4)alkyl, (C1-C4)alkoxy, —(CH2)p13-7 membered monocyclic heterocyclyl, —(CH2)p1NH3-7 membered monocyclic heterocyclyl, 5-6 membered heteroaryl, —O(CH2)p2NRaC(═O)(C1-C4)alkyl, —(CH2)p2O(CH2)p2O(C═O)(C1-C4)alkyl, or (CH2)p2NRaC(═O)(C1-C4)alkyl, wherein the alkyl, alkoxy, heteroaryl, or heterocyclyl represented by R3 or in the group represented by R3 is optionally substituted with one or more groups selected from the group consisting of halo, —CN, —OH, —(C1-C4)alkyl, —(C1-C4)haloalkyl, —(C1-C4)alkoxy, —(C1-C4)hydroxyalkyl, —(C1-C4)haloalkoxy, —(C1-C4)carboxyalkoxy, —S(O)2(C1-C4)alkyl, —(C1-C4)hydroxyalkoxy, and —NRaRa;
• each Ra is independently —H or —(C1-C4)alkyl;
• each Rb is independently —H or —(C1-C4)alkyl;
• wherein the —(C1-C4)alkyl represented by Rb is optionally substituted with one or more groups selected from halo, —CN, —OH, —(C3-C6)cycloalkyl, phenyl, 3-7 membered monocyclic heterocyclyl, and 5-6 membered heteroaryl;
• i is 0 or 1;
• k is 0, 1, 2, 3, or 4;
• m is 0, 1, 2, 3, or 4;
• n is 0, 1, 2, 3, or 4;
• p is 0, 1, 2, 3, or 4;
• p1 is 0, 1, 2, 3, or 4;
• and
• p2 is 2, 3, or 4.